Here we provide links to some of the key peer-reviewed publications behind the discovery and development of our immunotherapy technologies for glioblastoma multiforme (GBM) and other solid tumor cancers.
Recurrent glioblastoma treated with recombinant poliovirus – New England Journal of Medicine, June 2018.
When viruses attack – Nature Reviews: Cancer, October 2017.
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs – Science Translational Medicine, Sept. 2017.
Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models- Oncotarget, Oct. 2016.
Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus – Discovery Medicine, May 2015.
Induction of viral, 7-methyl-guanosine Cap-Independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase – Journal of Virology, Nov 2014.
Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis – Journal of Virology, March 2012.
Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype – Molecular Therapy, Nov 2008.
Intergeneric poliovirus recombinants for the treatment of malignant glioma – PNAS, June 2000.